Was this medicine useful for you?
What is Enstilar?
Enstilar contains a combination of Betamethasone (Enstilar) and Calcipotriene (Enstilar). Betamethasone (Enstilar) is a steroid. It prevents the release of substances in the body that cause inflammation. Calcipotriene (Enstilar) is a form of vitamin D. It works by decreasing the rate of skin cell reproduction.
Enstilar topical (for the skin) is a combination medicine used to treat plaque psoriasis.
Adults may use the suspension (liquid) form of this medicine on the skin or the scalp. The liquid may be used only on the scalp in children who are at least 12 years old.
Enstilar topical ointment should be used only on the skin and only by adults.
Enstilar® (Calcipotriene (Enstilar) and Betamethasone (Enstilar) dipropionate) Ointment is indicated for the topical treatment of psoriasis vulgaris in adults 18 years of age and above for up to 4 weeks. The maximum weekly dose should not exceed 100 g. Treatment of more than 30% body surface area is not recommended.
Enstilar® (Calcipotriene (Enstilar) and Betamethasone (Enstilar) dipropionate) Ointment should not be applied to the face, axillae or groin.
How should I use Enstilar?
Use Enstilar exactly as it was prescribed for you. Follow all directions on your prescription label. Do not use this medicine in larger or smaller amounts or for longer than recommended. Do not use Enstilar to treat any condition that has not been checked by your doctor.
Do not take Enstilar by mouth.
Topical medicine is for use only on the skin. Do not use in the vagina.
Read all patient information, medication guides, and instruction sheets provided to you. Ask your doctor or pharmacist if you have any questions.
Wash your hands before and after applying this medicine, unless you are using the medicine to treat the skin on your hands.
Shake the Enstilar suspension (liquid) just before using it.
Apply Enstilar once daily to the affected skin and rub it in gently. Do not spread the medicine over a large skin area. Do not apply to areas of thinner skin (face, underarms, groin) unless your doctor tells you to.
Do not cover the treated skin area. Covering skin treated with a topical steroid can increase the amount of medicine your skin absorbs, which may lead to unwanted side effects.
If you use Enstilar liquid:
Adults should not use more than 100 grams (1 full bottle) of the liquid in 1 week.
Children age 12 and older should not use more than 60 grams of the liquid in 1 week.
If you use Enstilar ointment: Do not use more than 100 grams (1 large tube) of the ointment in 1 week. Avoid treating an area that is larger than 30% or one-third of your entire body.
Ask your pharmacist if you have questions about how much to apply each time you use the medicine.
Enstilar ointment can be applied daily for up to 4 weeks. The liquid can be used daily for up to 8 weeks. Follow your doctor's instructions about your individual treatment schedule.
Call your doctor if your skin condition does not improve after several days of treatment, or if it gets worse while using this medicine.
If you use Enstilar long-term, you may need frequent medical tests.
Store at room temperature away from moisture and heat. Keep the bottle or tube tightly closed when not in use.
Stop using Enstilar when your skin clears up, unless your doctor tells you otherwise.
Uses of Enstilar in details
This product contains 2 drugs (Betamethasone (Enstilar) and Calcipotriene (Enstilar)) and is used to treat psoriasis of the scalp. Some brands of this medication are also used to treat psoriasis on the body. Betamethasone (Enstilar) is a very strong corticosteroid drug that helps decrease the swelling, redness, and itching of the skin that occurs with this condition. Calcipotriene (Enstilar), which is also known as calcipotriol in other countries, is a form of vitamin D. It works by slowing down the growth of skin cells so that they do not build up into thickened, scaly skin patches.
This medication should not be used if you have certain types of psoriasis (skin patches with pus-filled blisters, psoriasis with intense redness/shedding/oozing). Consult your doctor for more information.
This product is not recommended for use in children because they may be at an increased risk for side effects. See also Side Effects and Precautions sections.
How to use Enstilar topical
Read the Patient Information Leaflet provided by your pharmacist before you start using this product and each time you get a refill. If you have any questions, consult your doctor or pharmacist.
This medication is for use on the scalp. Do not apply this product 12 hours before or after any chemical treatments to your hair. Shake the bottle well before use. Part your hair, apply the product only to the affected area(s) of the scalp, and gently rub in, usually once daily or as directed by your doctor. Wash your hands after using, but do not wash your hair right after applying this product. Avoid getting any medication in the eyes or ears. If this occurs, immediately rinse with plenty of water. Do not apply this product to the face, underarms, or groin area.
If your doctor has directed you to use this product on your body, follow your doctor's directions for how much to use and where to use it. Apply to affected areas and gently rub in. Wash your hands after using.
Do not use this medication more often or for longer than directed. Do not use more than 100 grams of this product a week unless directed and closely monitored by your doctor. Do not bandage, wrap, or cover the treated area unless your doctor instructs you to do so. Do not use this product on large areas of damaged skin. Following these instructions helps to reduce your risk of side effects.
Tell your doctor if your condition does not improve or if it worsens. It may take up to 2 weeks to see any improvement.
Instruct patients to shake can prior to using Enstilar® Foam and to wash their hands after applying the product.
Apply Enstilar® Foam to affected areas once daily for up to 4 weeks. Rub in Enstilar® Foam gently. Discontinue use when control is achieved.
Instruct patients not to use more than 60 g every 4 days.
Enstilar® Foam should not be used with occlusive dressings unless directed by a physician. Enstilar® Foam is not for oral, ophthalmic, or intravaginal use.
Avoid use on the face, groin, or axillae, or if skin atrophy is present at the treatment site.
Dosage Forms And Strengths
Enstilar® Foam is a white to off-white opalescent liquid in a pressurized aluminum spray can with a continuous valve and actuator. At administration the product is a white to off-white foam after evaporation of the propellants. Each gram of Enstilar® Foam contains 52.2 mcg Calcipotriene (Enstilar) hydrate (equivalent to 50 mcg of Calcipotriene (Enstilar)) and 0.643 mg of Betamethasone (Enstilar) dipropionate (equivalent to 0.5 mg of Betamethasone (Enstilar)).
Storage And Handling
Enstilar® Foam is a white to off-white opalescent liquid in a pressurized aluminum spray can with a continuous valve and actuator. At administration the product is a white to off-white foam after evaporation of the propellants.
Enstilar® Foam is available in aluminum cans of:
1 x 60 g (NDC 50222-302-60)
2 x 60 g (NDC 50222-302-66)
- Store Enstilar® Foam at 20 °- 25°C (68° -77°F); excursions pe rmitted between 15 °-30°C (59°-86°F).
- Contents under pressure. Do not puncture or incinerate. Do not expose to heat or store at temperatures above 120°F (49°C). Do not freeze.
- The product should be used within six m onths after it has been opened.
- Enstilar® Foam is flammable; avoid heat, flame or smoking when using this product.
Manufactured by: Colep Laupheim GmbH & Co. KG Fockestra
Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.
Some products that may interact with this drug are:
other corticosteroid drugs (such as hydrocortisone, prednisone), other products containing Calcipotriene (Enstilar).
Enstilar side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.
The data described below reflect exposure to Enstilar® (Calcipotriene (Enstilar) and Betamethasone (Enstilar) dipropionate) Ointment in 2448 patients, including 1992 exposed for 4 weeks, and 289 exposed for 8 weeks. In the trials that included assessment of the effects of Enstilar® (Calcipotriene (Enstilar) and Betamethasone (Enstilar) dipropionate) Ointment on calcium metabolism, such testing was done after 4 weeks of treatment. The effects of Enstilar® (Calcipotriene (Enstilar) and Betamethasone (Enstilar) dipropionate) Ointment on calcium metabolism following treatment durations of longer than 4 weeks are not known. The effects of Enstilar® (Calcipotriene (Enstilar) and Betamethasone (Enstilar) dipropionate) Ointment on the HPA axis following treatment durations of longer than 4 weeks have not been adequately studied. Enstilar® (Calcipotriene (Enstilar) and Betamethasone (Enstilar) dipropionate) Ointment was studied primarily in placebo- and active-controlled trials (N = 1176, and N = 1272, respectively). The population was 15-97 years old, 61% males and 39% females, mostly white (97%) and had a baseline disease severity ranging from mild to very severe. Most patients received once daily application, and the median weekly dose was 24.5 g.
The percentage of subjects reporting at least one adverse event was 27.1% in the Enstilar® (Calcipotriene (Enstilar) and Betamethasone (Enstilar) dipropionate) Ointment group, 33.0% in the Calcipotriene (Enstilar) group, 28.3% in the Betamethasone (Enstilar) group, and 33.4% in the vehicle group.
| Enstilar® (Calcipotriene (Enstilar) and Betamethasone (Enstilar) dipropionate) |
| Calcipotriene (Enstilar) |
|Betamethasone (Enstilar) |
| Vehicle |
|Any Adverse Event||663 (27.1)||1055 (33.0)||329 (28.3)||157 (33.4)|
|Preferred Term||# of subjects (%)|
|Pruritus||75 (3.1)||183 (5.7)||38 (3.3)||43 (9.1)|
|Headache||69 (2.8)||75 (2.3)||44 (3.8)||12 (2.6)|
|Nasopharyngitis||56 (2.3)||77 (2.4)||34 (2.9)||9 (1.9)|
|Psoriasis||30 (1.2)||47 (1.5)||14 (1.2)||5 (1.1)|
|Rash scaly||30 (1.2)||40 (1.3)||0 (0.0)||1 (0.2)|
|Influenza||23 (0.9)||34 (1.1)||14 (1.2)||6 (1.3)|
|Upper respiratory||20 (0.8)||19 (0.6)||12 (1.0)||3 (0.6)|
|tract infection||15 (0.6)||54 (1.7)||3 (0.3)||5 (1.1)|
|Erythema Application site||13 (0.5)||24 (0.8)||10 (0.9)||6 (1.3)|
|pruritus||11 (0.4)||60 (1.9)||8 (0.7)||5 (1.1)|
|Skin irritation||7 (0.3)||12 (0.4)||3 (0.3)||5 (1.1)|
|Pain Burning sensation||6 (0.2)||30 (0.9)||3 (0.3)||6 (1.3)|
Adverse Events Reported by ≥ 1% of Subjects by Preferred Term
A lesional/perilesional adverse event was generally defined as an adverse event located ≤ 2 cm from the lesional border.
Lesional/Perilesional Adverse Events Reported by ≥ 1% of Subjects
| Enstilar® (Calcipotriene (Enstilar) and Betamethasone (Enstilar) dipropionate) |
| Calcipotriene (Enstilar) |
| Betamethasone (Enstilar) |
| Vehicle |
|Any Adverse Event||213 (8.7)||419 (13.1)||85 (7.3)||76 (16.2)|
|Preferred Term||# of subjects (%)|
|Pruritus||69 (2.8)||170 (5.3)||31 (2.7)||41 (8.7)|
|Rash scaly||29 (1.2)||38 (1.2)||0 (0.0)||0 (0.0)|
|Application site pruritus||12 (0.5)||24 (0.8)||10 (0.9)||6 (1.3)|
|Erythema||9 (0.4)||36 (1.1)||2 (0.2)||4 (0.9)|
|Skin irritation||9 (0.4)||51 (1.6)||8 (0.7)||5 (1.1)|
|Burning sensation||6 (0.2)||25 (0.8)||3 (0.3)||5 (1.1)|
For subjects who reported lesional/perilesional adverse events, the median time to onset was 7 days for Enstilar® (Calcipotriene (Enstilar) and Betamethasone (Enstilar) dipropionate) Ointment, 7 days for Calcipotriene (Enstilar), 5 days for Betamethasone (Enstilar) dipropionate, and 3 days for vehicle.
Other less common reactions (less than 1% but more than 0.1%) were, in decreasing order of incidence, folliculitis, rash papular, rash pustular, and skin hypopigmentation. Skin atrophy, telangiectasia and skin hyperpigmentation were reported infrequently (0.1%).
In a separate study, patients (N=207) with at least moderate disease severity were given Enstilar® (Calcipotriene (Enstilar) and Betamethasone (Enstilar) dipropionate) Ointment intermittently on an “as needed” basis for up to 52 weeks. The median use was 15.4 g per week. The effects of Enstilar® (Calcipotriene (Enstilar) and Betamethasone (Enstilar) dipropionate) Ointment on calcium metabolism were not studied and the effects on the HPA axis were not adequately studied. The following adverse reactions were reported by 1% or more of the patients: pruritus (7.2%), psoriasis (3.4%), skin atrophy (1.9%), folliculitis (1.4%), burning sensation (1.4%), skin depigmentation (1.4%), ecchymosis (1.0%), erythema (1.0%) and hand dermatitis (1.0%). One case of a serious flare-up of psoriasis was reported.
Development of pustular psoriasis has been reported as an adverse reaction during and following use of Enstilar® (Calcipotriene (Enstilar) and Betamethasone (Enstilar) dipropionate) Ointment.
Enstilar® (Calcipotriene (Enstilar) and Betamethasone (Enstilar) dipropionate) Ointment is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Enstilar® (Calcipotriene (Enstilar) and Betamethasone (Enstilar) dipropionate) Ointment is contraindicated in patients with known or suspected disorders of calcium metabolism.
Enstilar® (Calcipotriene (Enstilar) and Betamethasone (Enstilar) dipropionate) Ointment is contraindicated in patients with erythrodermic, exfoliative and pustular psoriasis.
Active ingredient matches for Enstilar:
Betamethasone/Calcipotriol in United States.
List of Enstilar substitutes (brand and generic names)
|Sort by popularity|
|Unit description / dosage (Manufacturer)||Price, USD|
|Daivobet (Australia, Bahrain, Bangladesh, Bulgaria, China, Colombia, Costa Rica, Czech Republic, Denmark, Dominican Republic, Ecuador, El Salvador, Estonia, Finland, France, Georgia, Germany, Guatemala, Honduras, Hong Kong, Iceland, India, Indonesia, Israel, Latvia, Lithuania, Malaysia, Malta, Norway, Panama, Philippines, Poland, Portugal, Romania, Russian Federation, Singapore, Slovenia, South Korea, Spain, Sweden, Switzerland, Taiwan, Tunisia, Uruguay, Vietnam)|
|Daivobet oint 30 g x 1's (Win Medicare Pvt Ltd)||$ 41.18|
|Daivobet gel 15 g x 1's (Win Medicare Pvt Ltd)|
|Daivobet gel 30 g x 1's (Win Medicare Pvt Ltd)||$ 41.98|
|Daivobet gel 60 g x 1's (Win Medicare Pvt Ltd)|
|DAIVOBET oint 15g (Win Medicare Pvt Ltd)||$ 12.29|
|Daivobet 50 µg/0.5 mg/g (Hungary)|
|Daivobet 50 µg/g + 0,5 mg/g (Austria, Germany)|
|Daivobet 50/500 (Australia, New Zealand)|
|Daivobet D.A.C. (Iceland)|
|Dovobet Ointment (United Kingdom)|
|Dyvon Plus (Bangladesh)|
|Enstilar 50 μg/g + 0.5 mg/g (Austria)|
|Enstilum (Belgium, Romania)|
|Enstilum 50mcg/0.5mg (Luxembourg)|
|Psorcutan Beta (Germany, Turkey)|
|Taclonex (Argentina, United States)|
|Ointment; Topical; Betamethasone Dipropionate 0.064%; Calcipotriol Hydrate 0.005% (Warner chilcott)|
|100 gram in 1 tube (Warner chilcott)|
|3 gram in 1 tube (Warner chilcott)|
|60 gram in 1 tube (Warner chilcott)|
|Suspension; Topical; Betamethasone Dipropionate 0.064%; Calcipotriol Hydrate 0.005%|
|Taclonex Scalp Suspension|
|Taclonex Scalp topical|
|Xamiol (Austria, Belgium, Bulgaria, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Iceland, Italy, Latvia, Lithuania, Luxembourg, Malta, Norway, Oman, Philippines, Portugal, Slovenia, Sweden, Switzerland, Taiwan, Tunisia)|
|Gel; Topical; Betamethasone Dipropionate 0.5 mg; Calcipotriol Monohydrate 50 mcg / g (LEO Pharma)|
|Xamiol 30 g (LEO Pharma)||$ 41.98|
|Xamiol 15 g x 1's (LEO Pharma)|
|Xamiol 15 g (LEO Pharma)|
|Xamiol topical gel 30 g x 1's (LEO Pharma)||$ 41.98|
|Xamiol topical gel 15 g x 1's (LEO Pharma)|
|Xamiol 50 Mikrogramm/g + 0,5 mg/g (Germany)|
|Xamiol 50µg/0.5mg/g (Hungary, Luxembourg)|
- DailyMed. "CALCIPOTRIENE HYDRATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DailyMed. "BETAMETHASONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "betamethasone". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
ReviewsThe results of a survey conducted on ndrugs.com for Enstilar are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Enstilar. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Consumer reported usefulNo survey data has been collected yet
1 consumer reported price estimatesWas the price you paid to purchase the drug reasonable? Did you feel it was expensive?
The below mentioned numbers have been reported by ndrugs.com website users about whether the Enstilar drug is expensive or inexpensive. There is a mixed opinion among users. The rating about the cost of the drug depends on factors like which brand drug the patient purchased, how effective it was for the price paid, the country or place the drug is marketed, and the economic condition of the patient. The users who feel the drug is expensive can look for an alternative brand drug or a generic drug to save the cost.
Consumer reported time for resultsNo survey data has been collected yet
6 consumers reported age
There are no reviews yet. Be the first to write one!
Information checked by Dr. Sachin Kumar, MD Pharmacology